NRD
CYTK icon

Nebula Research & Development’s Cytokinetics CYTK Stock Holding History

Nebula Research & Development’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-12,411
Closed -$410K – 247
2025
Q2 		$410K Buy
12,411
+246
+2% +$8.56K 0.03% 693
2025
Q1 		$489K Buy
+12,165
New +$559K 0.05% 616

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Nebula Research & Development's CYTK Position: Q3 2025 in Review

Nebula Research & Development sold out of Cytokinetics (CYTK) in Q3 2025, closing a stake of 12,411 shares — an estimated $410K sold.

Nebula Research & Development first reported a position in CYTK in Q1 2025 and held it in 2 quarters. The position peaked at $489K in Q1 2025. 380 funds tracked by Wall St. Rank hold CYTK as of Q3 2025.

  • Nebula Research & Development reported no remaining Cytokinetics position as of Q3 2025 after selling out during the quarter.
  • Nebula Research & Development sold 12,411 Cytokinetics shares in Q3 2025, an estimated $410K.
  • Nebula Research & Development first reported a position in Cytokinetics in Q1 2025 and held it in 2 quarters.
  • Nebula Research & Development's Cytokinetics position peaked at $489K in Q1 2025.
  • 380 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2025.

Based on Nebula Research & Development's 13F filing for Q3 2025.